

Develop the Next Wave of Breakthroughs



Program	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Registration	Marketed
NUPLAZID® (pimavanserin)¹	Parkinson's Disease Psychosis	[Progress bar spanning Preclinical, Phase 1, Phase 2, Phase 3, and Registration]					
Trofinetide²	Rett Syndrome	[Progress bar spanning Preclinical, Phase 1, Phase 2, and Phase 3]					
Pimavanserin³	Negative Symptoms of Schizophrenia	[Progress bar spanning Preclinical, Phase 1, and Phase 2]					
ACP-204	Neuropsychiatric Indications	[Progress bar spanning Preclinical and Phase 1]					
ASO Programs⁴	SYNGAP1; Rett Syndrome; Undisclosed	[Progress bar in Preclinical]					
Other Programs	Neuropsychiatric Symptoms	[Progress bar in Preclinical]					

¹NUPLAZID (pimavanserin) is only approved in the U.S. by the FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

²Acadia has an exclusive license to develop and commercialize trofinetide in North America from Neuren Pharmaceuticals. Trofinetide is an investigational agent, and its safety and efficacy have not been established. There is no guarantee these investigational agents will be filed with or approved by any regulatory agency.

³Safety and Efficacy of NUPLAZID for the treatment of negative symptoms of schizophrenia have not been established or approved by the FDA.

⁴Acadia entered into a collaboration with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases.

ASO = Antisense oligonucleotide.

Provided August 8, 2022 as part of an oral presentation and is qualified by such; contains forward-looking statements; actual results may vary materially; Acadia disclaims any duty to update.